Donald D. Charron
Analyst · B. Riley. Your line is now open
Thank you Raniya and welcome everyone to our third quarter conference call. Our earnings release was issued yesterday afternoon on the results of our third quarter ended March 31, 2016. We have posted a financial summary presentation to accompany this conference call. The presentation can be found on our Investor Relations website within the Events and Presentations tab, or if you are listening via the webcast, you can find it in the Downloads tab on the webcast portal. I will begin by making a few remarks on the overall quarter and then I will turn it over to Mike for the financial overview. After that, we will answer any questions that you may have. Our sales in the third quarter of fiscal year 2016 improve slightly over both of previous quarter and the same quarter last year. Led by a double-digit increase in China and further strengthening in Europe. Sales in our automotive end-market vertical were up 14% when compared to the same quarter last year. We completed the launch and transition from our current and next generation product for one of our largest customers, which helped to increase the sales on our medical vertical by 10% when compared to the third quarter of fiscal year 2015. Our sales in our public safety end-market vertical were down 8% year-over-year on lower demand. And our sales in the industrial end-market vertical were down 11% when compare to the third quarter of fiscal year 2015. However, we were encouraged by the sequential increase in our sales in the industrial end-market vertical, which were up 7% from the second quarter. We are making good progress on the launches of a number of new business awards with both existing and new customers. We are expecting sales from these launches starting in the fourth quarter of this fiscal year. Now our new business opportunities pipeline remains healthy and we continue to work diligently to achieve our medium range goal of $1 billion in annual sales by fiscal year 2018. As we have stated previously, over the last few quarters and continuing in this quarter, our operating margin is under pressure due to incremental cost related to the Romania Greenfield start-up and capital deployments for new customer programs in advance of revenue. Margin improvement through cost control and productivity improvements continues to be a high focused are for us, as we remain committed to our 4% operating income goal. We continue to excellent progress in Romania, since completing the construction of a new facility in November 2015, we went live with our ERP system and passed our ISO quality management system certification audit. We also hosted several customer audit and during this past quarter, we received approval from one of our industrial customer to begin production. Also during this past quarter, we produced validation units for one of our automotive customers. Once we receive the customer approval, we expect a steady ramp up of revenue over a multi quarter period. We continue to take advantage of the flexibility provided by our strong balance sheet, making investments that will drive future growth in sales and profits. After investing $37 million in capital expenditures in fiscal year 2015, we are on pace and expect to invest slightly more than that in capital investments in fiscal year 2016, with the largest portion of these capital expenditures directly supporting new business awards. We are focused on getting to the launch cycle, ramping up production and ensuring that these new program and the newly deployed capital that supports them to achieve our expected returns. During the third quarter of fiscal year 2016, we also returned $4.4 million to our shareowners by purchasing 402,000 shares of our common stock, which brings our total to $8.2 million and 745,000 share purchased under the $20 million share repurchase program approved by our Board in October of 2015. And finally, we are excited about the Medivative acquisition which we closed on May 2, and was disclosed in our Form 8-K yesterday. Medivative adds capabilities in the clinical design, precision plastics, combination devices, instruments and complex system assembly to our overall package of value and positions us to better serve both existing and new customers in our medical end-market vertical. Medivative has been successful building long term relationships with a number of well known medical and bioscience customers and we look forward to growing relationships in the future as Medivative becomes a unit of Kimball Electronics. Now I will turn it over to Mike to discuss our third quarter results in more detail. We will then open the call to your questions. Mike.